NCT05753189

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 362 (actual)
• Sponsor: LENZ Therapeutics, Inc · Academic / Other
• Sex: All
• Age: 45 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Detailed description

Safety Study: Multi-Center, Double-Masked Phase 3 Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects

Conditions

• Presbyopia
• Near Vision
• Miosis
• Eye Diseases

Interventions

Type	Name	Description
DRUG	Aceclidine+Brimonidine combination ophthalmic solution	Combination ophthalmic solution of Aceclidine and Brimonidine
DRUG	Placebo	Placebo: Proprietary Vehicle Solution
DRUG	Aceclidine Ophthalmic Solution	Aceclidine

Timeline

• Start date: 2023-02-21
• Primary completion: 2024-02-09
• Completion: 2024-02-09
• First posted: 2023-03-03
• Last updated: 2024-12-18

Locations

36 sites across 1 country: United States

Regulatory

• FDA-regulated drug study